BTX-A51 (E1455-GRP)

BTX-A51 (Casein Kinase inhibitor A51) is a first-in-class oral and potent inhibitor of casein kinase 1α (CK1α) and cyclin dependent kinase (CDK7/9) with an IC50 of 17 nM for CK1α and Kd of 1.3 nM and 4 nM for CDK7 and CDK9, respectively. It induces apoptosis of leukemic cells by activating p53 and inhibiting expression of Mcl1 and can be used in Acute myeloid leukemia (AML) cancer research.